In this first episode of the Yeah No Journal Club, we take a joyful romp through the X:BOT study to tackle two important questions. (1) Is extended-release naltrexone or daily buprenorphine-naloxone more effective for treating adults with opioid use disorder? (2) Why does it matter if a study uses a per-protocol or intent-to-treat analysis**? It turns out that getting an answer to the first question requires understanding the second one.

**And don't worry if you don't know what a per protocol or intent to treat analysis is--you will after listening to this.

(Adriane dela Cruz, M.D., Ph.D., is an Assistant Professor of Psychiatry at UT Southwestern Medical Center and with the Peter O’Donnell Jr. Brain Institute who focuses on treating patients with drug and alcohol addictions. The opinions expressed are her own and do not reflect those of UT Southwestern, the O’Donnell Brain Institute, the UT System, or the state.)